Benjamin Besse

50PUBLICATIONS

594CO-AUTHORS

Molecular targetsPredictive and prognostic markersCellular immunologyCancer therapy (excl. chemotherapy and radiation therapy)Computational neuroscience (incl. mathematical neuroscience and theoretical neuroscience)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (50)

Sort by Publication Date:

|Jun 22, 2026

Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer.

|Jun 01, 2026

Selpercatinib in Early-Stage <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer.

|May 08, 2026

Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.

|Apr 07, 2026

Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.

Arianna Marinello, Julia K Rotow, Meghanne Lomibao

|Mar 26, 2026

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer.

Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano

|Feb 04, 2026

Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial.

Benjamin Besse, Jessica J Lin, Lyudmila Bazhenova

Pageof 9

Frequent Collaborators

11 joint publications

Ludovic Lacroix

10 joint publications

Luc Friboulet

Mihaela Aldea

Yohann Loriot

Jean-Yves Scoazec

Fabrice Andre

Antoine Italiano

Jordi Remon

Alexander Drilon

Antoine Hollebecque

Frequent Collaborators

11 joint publications

Ludovic Lacroix

10 joint publications

Luc Friboulet

9 joint publications

Mihaela Aldea

9 joint publications

Yohann Loriot